About Novartis
We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Access
We are committed to bringing more of our medicines to more people, no matter where they are.
People and Culture
Novartis is building an Inspired, Curious and Unbossed culture.
Compassionate use: Providing access to much needed treatments
What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.
Latest news
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
World Economic Forum (WEF) 2023
Novartis leaders will be at the WEF Annual Meeting in Davos, Switzerland
Sandoz spin-off
Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.
The Novartis Commitment to Patients and Caregivers
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
Live Magazine
Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.